These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31298463)

  • 1. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
    Desai RJ; Kim SC; Curtis JR; Bosco JLF; Eichelberger B; Barr CE; Lockhart CM; Bradbury BD; Clewell J; Cohen HP; Gagne JJ;
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):757-769. PubMed ID: 31298463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care.
    McMahill-Walraven CN; Kent DJ; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1156-1161. PubMed ID: 31397619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
    Cohen HP; Hachaichi S; Bodenmueller W; Kvien TK; Danese S; Blauvelt A
    BioDrugs; 2022 Sep; 36(5):625-637. PubMed ID: 35881304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims.
    Zhang J; Haynes K; Mendelsohn AB; Marshall J; Barr CE; McDermott C; Brown J; Kline A; Kenney J; King KJ; Holmes C; Yeung K; Barron J; Yun H; Lockhart CM
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):778-785. PubMed ID: 31802568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.
    Herndon TM; Ausin C; Brahme NN; Schrieber SJ; Luo M; Andrada FC; Kim C; Sun W; Zhou L; Grosser S; Yim S; Ricci MS
    PLoS One; 2023; 18(10):e0292231. PubMed ID: 37788264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.
    Edwards CJ; Hercogová J; Albrand H; Amiot A
    Expert Opin Biol Ther; 2019 Oct; 19(10):1001-1014. PubMed ID: 31056970
    [No Abstract]   [Full Text] [Related]  

  • 11. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Analysis of Biosimilar Switching Studies.
    Chow SC; Lee SJ
    Pharmaceut Med; 2019 Oct; 33(5):379-388. PubMed ID: 31933227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design of clinical trials to support the switching and alternation of biosimilars.
    Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengths, weaknesses and future challenges of biosimilars' development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice.
    Scavone C; Rafaniello C; Berrino L; Rossi F; Capuano A
    Pharmacol Res; 2017 Dec; 126():138-142. PubMed ID: 29113760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany
.
    Reuber K; Kostev K
    Int J Clin Pharmacol Ther; 2019 Jun; 57(6):323-328. PubMed ID: 30990409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment of biosimilars worldwide: a scoping review.
    Ascef BO; Lopes ACF; de Soárez PC
    Health Res Policy Syst; 2020 Aug; 18(1):95. PubMed ID: 32843051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.